Commentary on “Preventive percutaneous coronary intervention versus optimal medical therapy alone for the treatment of vulnerable atherosclerotic coronary plaques (PREVENT): a multicenter, open-label, randomized controlled trial”

To address the potential risk of acute coronary syndrome, the current clinical guidelines on coronary artery diseases recommend revascularization in significant and flow-limiting lesions, but emerging data depict vulnerable atherosclerotic coronary plaques as possibly at risk of adverse cardiac events, compared to fibroatheromous or calcific plaques [...].